FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4246571909> ?p ?o ?g. }

• W4246571909 endingPage "1622" @default.
• W4246571909 startingPage "1616" @default.
• W4246571909 abstract "Objective: Much debate exists on the initiation of chemotherapy for women at risk for persistent gestational trophoblastic disease. This is a result of a lack of early Predictors for the development of persistent gestational troPhoblastic disease after evacuation of a complete hydatidiform mole because the only current reliable method of detection and diagnosis lies in persistent or rising Postmolar R-human chorionic 9onadotroPin values. We used immunocytochemical techniques to retrospectively study the expression of the c-erb B-2 onco9ene product in formalin-fixed, paraffin-embedded troPhoblastic tissues as a potential indicator of the development of persistent gestational trophoblastic disease. Study Design: In this retrospective study 56 trophoblastic tumors were examined b means of immunocytochemical techniques to stain for the onco9ene product for evidence of c-erb B-2 expression. Our 56 cases included original tissue from 20 cases of complete mole that progressed to persistent gestational trophoblastic disease, seven cases of choriocarcinoma after term pregnancy or abortion and 29 cases of hYdatidiform mole representing Postevacuation, spontaneously regressing disease (including one partial mole). We also studied 11 cases of first-trimester trophoblast and 15 cases of term placenta as additional controls. Results: Our results showed positive immunostainin9 for c-erb B-2 gene product in one case of persistent gestational troPhoblastic disease, with negative staining in all other cases in the study groups and controls. Conclusion: Analysis for the significance of c-erb B-2 expression in persistent gestational trophoblastic disease showed that this correlation between c-erb B-2 expression and persistent gestational troPhoblastic disease is not significant, suggesting that future efforts should be directed at the involvement of different oncoproteins. Objective: Much debate exists on the initiation of chemotherapy for women at risk for persistent gestational trophoblastic disease. This is a result of a lack of early Predictors for the development of persistent gestational troPhoblastic disease after evacuation of a complete hydatidiform mole because the only current reliable method of detection and diagnosis lies in persistent or rising Postmolar R-human chorionic 9onadotroPin values. We used immunocytochemical techniques to retrospectively study the expression of the c-erb B-2 onco9ene product in formalin-fixed, paraffin-embedded troPhoblastic tissues as a potential indicator of the development of persistent gestational trophoblastic disease. Study Design: In this retrospective study 56 trophoblastic tumors were examined b means of immunocytochemical techniques to stain for the onco9ene product for evidence of c-erb B-2 expression. Our 56 cases included original tissue from 20 cases of complete mole that progressed to persistent gestational trophoblastic disease, seven cases of choriocarcinoma after term pregnancy or abortion and 29 cases of hYdatidiform mole representing Postevacuation, spontaneously regressing disease (including one partial mole). We also studied 11 cases of first-trimester trophoblast and 15 cases of term placenta as additional controls. Results: Our results showed positive immunostainin9 for c-erb B-2 gene product in one case of persistent gestational troPhoblastic disease, with negative staining in all other cases in the study groups and controls. Conclusion: Analysis for the significance of c-erb B-2 expression in persistent gestational trophoblastic disease showed that this correlation between c-erb B-2 expression and persistent gestational troPhoblastic disease is not significant, suggesting that future efforts should be directed at the involvement of different oncoproteins." @default.
• W4246571909 created "2022-05-12" @default.
• W4246571909 creator A5009447210 @default.
• W4246571909 creator A5014552488 @default.
• W4246571909 creator A5080534060 @default.
• W4246571909 date "1994-05-01" @default.
• W4246571909 modified "2023-09-26" @default.
• W4246571909 title "Expression of c-erb B-2 oncogene product in persistent gestational trophoblastic disease" @default.
• W4246571909 doi "https://doi.org/10.1016/s0002-9378(12)91825-6" @default.
• W4246571909 hasPublicationYear "1994" @default.
• W4246571909 type Work @default.
• W4246571909 citedByCount "0" @default.
• W4246571909 crossrefType "journal-article" @default.
• W4246571909 hasAuthorship W4246571909A5009447210 @default.
• W4246571909 hasAuthorship W4246571909A5014552488 @default.
• W4246571909 hasAuthorship W4246571909A5080534060 @default.
• W4246571909 hasConcept C131872663 @default.
• W4246571909 hasConcept C142724271 @default.
• W4246571909 hasConcept C172680121 @default.
• W4246571909 hasConcept C2776571570 @default.
• W4246571909 hasConcept C2776953305 @default.
• W4246571909 hasConcept C2777495146 @default.
• W4246571909 hasConcept C2778383414 @default.
• W4246571909 hasConcept C2779134260 @default.
• W4246571909 hasConcept C2779234561 @default.
• W4246571909 hasConcept C2780343435 @default.
• W4246571909 hasConcept C2780572646 @default.
• W4246571909 hasConcept C2780832733 @default.
• W4246571909 hasConcept C2908941940 @default.
• W4246571909 hasConcept C2909081632 @default.
• W4246571909 hasConcept C29456083 @default.
• W4246571909 hasConcept C46973012 @default.
• W4246571909 hasConcept C54355233 @default.
• W4246571909 hasConcept C71924100 @default.
• W4246571909 hasConcept C86803240 @default.
• W4246571909 hasConceptScore W4246571909C131872663 @default.
• W4246571909 hasConceptScore W4246571909C142724271 @default.
• W4246571909 hasConceptScore W4246571909C172680121 @default.
• W4246571909 hasConceptScore W4246571909C2776571570 @default.
• W4246571909 hasConceptScore W4246571909C2776953305 @default.
• W4246571909 hasConceptScore W4246571909C2777495146 @default.
• W4246571909 hasConceptScore W4246571909C2778383414 @default.
• W4246571909 hasConceptScore W4246571909C2779134260 @default.
• W4246571909 hasConceptScore W4246571909C2779234561 @default.
• W4246571909 hasConceptScore W4246571909C2780343435 @default.
• W4246571909 hasConceptScore W4246571909C2780572646 @default.
• W4246571909 hasConceptScore W4246571909C2780832733 @default.
• W4246571909 hasConceptScore W4246571909C2908941940 @default.
• W4246571909 hasConceptScore W4246571909C2909081632 @default.
• W4246571909 hasConceptScore W4246571909C29456083 @default.
• W4246571909 hasConceptScore W4246571909C46973012 @default.
• W4246571909 hasConceptScore W4246571909C54355233 @default.
• W4246571909 hasConceptScore W4246571909C71924100 @default.
• W4246571909 hasConceptScore W4246571909C86803240 @default.
• W4246571909 hasIssue "5" @default.
• W4246571909 hasLocation W42465719091 @default.
• W4246571909 hasOpenAccess W4246571909 @default.
• W4246571909 hasPrimaryLocation W42465719091 @default.
• W4246571909 hasRelatedWork W1558526078 @default.
• W4246571909 hasRelatedWork W183499939 @default.
• W4246571909 hasRelatedWork W1966684953 @default.
• W4246571909 hasRelatedWork W2078135249 @default.
• W4246571909 hasRelatedWork W2200970150 @default.
• W4246571909 hasRelatedWork W2220525436 @default.
• W4246571909 hasRelatedWork W2770657147 @default.
• W4246571909 hasRelatedWork W4302425029 @default.
• W4246571909 hasRelatedWork W79164028 @default.
• W4246571909 hasRelatedWork W3129789156 @default.
• W4246571909 hasVolume "170" @default.
• W4246571909 isParatext "false" @default.
• W4246571909 isRetracted "false" @default.
• W4246571909 workType "article" @default.